Nurix Therapeutics, Inc. (NRIX)

NGM – Real vaqt narxi. Valyuta: USD

25.34

-0.17 (-0.67%)

Yopilishda: Oct 23, 2026, 3:59 PM EDT

25.34

0.00 (0.00%)

Bozordan keyin: Oct 23, 2026, 4:00 PM EDT

14.10.2026

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.

12.10.2026

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.

12.10.2026

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

07.10.2026

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

05.10.2026

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by an additional two years.

29.09.2026

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs).

17.09.2026

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Videolar

No Data

There is no data to display

Press-relizlar

12.10.2026

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

07.10.2026

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

05.10.2026

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

29.09.2026

Nurix Therapeutics, Inc. (NRIX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Biz bilan bog'lanish

Bizni kuzating

Nurix Therapeutics, Inc. (NRIX)

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Videolar

No Data

Press-relizlar

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Videolar

No Data

Press-relizlar

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Search stocks

Nurix Therapeutics, Inc. (NRIX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Biz bilan bog'lanish

Bizni kuzating

Nurix Therapeutics, Inc. (NRIX)

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Videolar

No Data

Press-relizlar

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Videolar

No Data

Press-relizlar

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer